Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Updated Oct 7, 2026
AI dilution summary: the dominant contractual driver and its mechanism, then each further driver ranked, for Signal8 Pro subscribers.
